Shuanglu Pharmaceutical Co., Ltd. is a high-tech enterprise mainly engaged in genetic engineering and research, development, production and operation in biochemical drugs. It is the first listed company in Beijing to land on the SME board and is a nationally recognized enterprise technology center. Mainly engaged in the research and development, production and management of genetic engineering drugs.
Changchun High-tech: At the same time, 9 products are being developed, 8 of which are related to genetic engineering. The project mainly aims at recombinant human growth hormone injection and recombinant human follicle-stimulating hormone for infertility. At present, among its long-acting auxin projects, the project for slow growth of children caused by endogenous growth hormone deficiency has been declared for production and is being approved. Another recombinant human follicle-stimulating hormone for injection for infertility has also been declared for production and is awaiting approval. The remaining six recombinant human growth hormone injections are still in clinical research or in the process of waiting for approval of clinical research.
Shu Taishen: Three R&D projects, including gene drugs for treating retinitis pigmentosa, small nucleic acid gene drugs for anti-HBV, and small nucleic acid gene drugs for anti-AIDS, have all completed some basic pharmaceutical research work.
tonghua dongbao: The core genetic engineering project-Y-PEGylated recombinant human interferon α2b injection (Class I) has started phase III clinical research, which is the most important research and development project in tonghua dongbao. In the field of biopharmaceuticals, the company's product "Ganshulin" fills the gap in China, making China a country that can produce recombinant human insulin and glargine insulin after the United States and Denmark. At present, the second phase expansion project of Dongbao gene recombinant human insulin, a key project supported by the state to revitalize the old industrial base in Northeast China with a total investment of 35 million yuan, is introducing and installing advanced foreign equipment, and the company has become one of the largest human insulin production bases in China.
Fosun Pharma: Fosun Pharma's recombinant erythropoietin for anemia and recombinant human insulin for diabetes are also under development. The company is a leading listed company in China pharmaceutical industry, focusing on modern biomedical health industry. Grasping the rapid growth of China's pharmaceutical market and the great opportunity for China enterprises to enter the mainstream pharmaceutical market in the world, the company strategically covers many important links in the pharmaceutical health industry chain, such as R&D and manufacturing, distribution and terminals, and has formed a large-scale professional pharmaceutical health industry group with pharmaceutical R&D and manufacturing as the core, and at the same time has a leading market position in the fields of pharmaceutical circulation, medical services, medical diagnosis and medical devices, and has formed competitive advantages in R&D and innovation, marketing, merger and acquisition, and talent construction.
Haizheng Pharmaceutical Co., Ltd.: The recombinant human tumor necrosis factor receptor II-Fc fusion protein (Anbainuo) of Haizheng Pharmaceutical Co., Ltd., the third phase of clinical practice is over, and it needs to be approved by the Food and Drug Administration. The company is a leading manufacturer of raw materials in China and one of the largest production bases of antibiotics and anti-tumor drugs in China. Its research and development fields cover chemical synthesis, microbial fermentation, biotechnology, natural plant extraction and preparation development, and its product treatment fields involve anti-tumor, cardiovascular system, anti-infection, anti-parasite, endocrine regulation, immunosuppression and anti-depression.
anke biotechnology: anke biotechnology's gene leading products, such as recombinant human interferon α2b (Andafen) series preparations, recombinant human growth hormone (Ansumeng) and anti-sperm antibody detection (MAR) kit, are independently developed by Anke, and are playing an increasingly important role in the detection and treatment of hepatitis B, tumor, leukemia growth failure, nutritional support, burns, immune infertility and other frequently-occurring and difficult diseases. The leading products, recombinant human interferon and recombinant human growth hormone, rank among the top in the domestic market share and have successfully entered the international market.
reprinted from China's first stock information aggregation platform-Yuncaijing. com.